The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1356
Botulinum Toxin for Chronic Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved injection of onabotulinumtoxinA (Botox – Allergan) for prevention of headaches in adult patients with chronic migraine (≥15 headache days/month for ≥3 months). It is the first drug approved for treatment of this indication. Botox is also FDA-approved for treatment of upper limb spasticity, axillary hyperhidrosis, cervical dystonia, blepharospasm and strabismus, and for cosmetic reduction of wrinkles.

MIGRAINE PROPHYLAXIS — Beta-blockers and tricyclic antidepressants are commonly prescribed for prevention of episodic or chronic migraine. In randomized controlled trials, the efficacy of the antiepileptic drugs valproate (Depakote, and others) and topiramate (Topamax, and others) in preventing episodic migraine was similar to that of propranolol. Topiramate has also reduced the number of migraine headaches per month in patients with chronic migraine. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Botulinum Toxin for Chronic Migraine
Article code: 1356b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian